Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors
Complete Title: PEPN2112: A Phase 1/ 2 Study of BAY 1895344 (elimusertib, IND#152153, NSC#810486) in Pediatric Patients with Relapsed or Refractory Solid Tumors
Trial Phase: I/II
Investigator: Navin Pinto, MD
This phase I/II trial tests the safety, best dose, and whether elimusertib works in treating patients with solid tumors that have come back (relapsed) or does not respond to treatment (refractory). Elimusertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Keywords:
- Lymphoma
- Rhabdomyosarcoma
- Sarcoma, Ewing
- Neoplasms, Malignant
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
Pediatric
I/II
Navin Pinto, MD
RG1122517
NCT05071209
PEPN2112: A Phase 1/ 2 Study of BAY 1895344 (elimusertib, IND#152153, NSC#810486) in Pediatric Patients with Relapsed or Refractory Solid Tumors
Lymphoma
Rhabdomyosarcoma
Sarcoma, Ewing
Neoplasms, Malignant